SynthesisFrontiers in oncology2022

Beyond Crizotinib: A Systematic Review and Meta-Analysis of the Next-Generation ALK Inhibitors as First-Line Treatment for ALK-Translocated Lung Cancer.

Emilio Francesco Giunta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.